Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice

Journal of Autoimmunity

Volumn 9, Issue 6, 1996, Pages 713-721

  Sai P ^a,c   Damge Ch ^b   Rivereau, A S ^a   Hoeltzel, A ^b   Gouin, E ^a  

^a University School of Medicine   (France)

^b University of Strasbourg   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

diabetes; insulin; nanocapsules; NOD mice; prevention

Indexed keywords

BUCRILATE; CYCLOPHOSPHAMIDE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG THERAPY; ETIOLOGY; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; INTESTINE ABSORPTION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREVENTION; PRIORITY JOURNAL;

EID: 0030474308     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0093     Document Type: Article

References (46)

1. 1. Thai A.C., Eisenbarth G.S. 1993. Natural history of IDDM. Diabetes Reviews 1: 1-14
2. 2. Castano L., Eisenbarth G.S. 1990. Type 1 diabetes: a chronic autoimmune disease of man, mouse and rat. Annu. Rev. Immunol. 8: 647-679
3. 3. Bowman M.A., Leiter E.H., Atkinson M.A. 1994. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol. Today 15: 115-120
4. 4. Skyler J.S., Marks J.B. 1993. Immune intervention in type 1 diabetes mellitus. Diabetes Review 1: 15-42
5. 5. Maclaren N.D. 1988. How, when and why to predict IDDM. Diabetes 37: 1591-1594
6. 6. Tarn A.C., Thomas J.M., Dean B.M., Schwartz G., Ingram D., Bottazzo G.F., Gale E.A.M. 1988. Predicting insulin-dependent diabetes. Lancet I: 845-850
7. 7. Shah S.C., Malone J.I., Simpson N.E. 1989. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes. N. Engl. J. Med. 320: 550-554
8. 8. Atkinson M.A., Maclaren N.K., Luchetta R. 1990. Insulitis and diabetes in NOD mice are reduced by prophylactic insulin therapy. Diabetes 39: 933-937
9. 9. Godfredson G.F., Buschard K., Frandson E.K. 1985. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 28: 933-935
10. 10. Like A.A. 1986. Insulin injections prevent diabetes in BioBreeding/Worcester rats. Diabetes 12848: 12336-14128 (Abstract)
11. 11. Keller R.J., Eisenbarth G.S., Jackson R.A. 1993. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341: 927-928
12. 12. Appel M.C., Dotta F., O'Neill J.J., Eisenbarth G.S. 1989. β-cell activity regulates the expression of islet antigenic determinants. Diabetologia 32: A461 (Abstract)
13. 13. Bieg S., Bailyes E.M., Yassin N., Amann J., Herberg L., McGregor A.M., Scherbaum W.A., Björk E., Kämpe O., Anderson A., Karlsson F.A. 1992. Expression of the 64KDa/glutamic acid decarboxylase rat islet cell autoantigen is influenced by the rate of insulin secretion. Diabetologia 32: 490-493
14. 14. Kämpe O., Andersson A., Björk E., Hallberg A., Karlsson F.A. 1989. High-glucose stimulation of 64.000-Mr islet cell autoantigen expression. Diabetes 38: 1326-1328
15. 15. Senecat O., Martignat L., Elmansour A., Audrain M., Julien J.F., Saï P. 1994. Diabetes enhancement of diabetes and increased islet antigen expression in NOD mice following neonatal injections of glucose and arginine. Metabolism 43: 1-10
16. 16. Aprahamian M., Michel C., Humbert W., Devissaguet J.P., Damgé C. 1987. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol. Cell. 61: 69-76
17. 17. Damgé C., Michel C., Aprahamian M., Couvreur P. 1988. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37: 246-251
18. 18. Lenaerts V., Couvreur P., Christiaens-Leyh D., Joiris E., Roland M., Rollman B., Speiser P. 1984. Degradation of poly(isobutylcyanoacrylate) nanoparticles. Biomaterials 5: 65-68
19. 19. Damgé C., Hillaire-Buys D., Puech R., Hoeltzel A., Michel C., Ribes G. 1995. Effects of orally administered insulin nanocapsules in normal and diabetic dogs. Diabetes Nutrition & Metabolism 8: 3-9
20. 20. Bone A.J., Barley J., Winwood D., Ekwuribe N., Rosenburg B., Radhakrishnan B. 1994. Successful treatment of the insulin dependent diabetic BB/S rat with orally-active insulin. Diabetes 37, supplement 1, A14, 632 (Abstract)
21. 21. Saï P., Elmansour A., Audrain M., Charbonnel B., Bardet S. 1993. Quantification of human islet-cell antibodies which cross-react with mouse pancreas: a follow-up study in type 1 diabetic patients and in first-degree relatives. Diabetologia 36: 778-784
22. 22. Chaillous L., Delamaire M., Elmansour A., Maugendre D., Rohmer V., Joseph M.G., Lecomte P., Limai J.M., Charbonnel B., Allannic H., Saï P. 1994. Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the Mr 64,000 islet protein and antibodies to glutamate decarboxylase in subjects at risk for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 37: 491-499
23. 23. Chaillous L., Delamaire M., Maugendre D., Marre M., Charbonnel B., Allannic H., Saï P. 1994. Analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the Mr 64,000 protein, and antibodies to intact glutamate decarboxylase, in Type 1 diabetic patients. Diabetes Care 17: 115-1123
24. 24. Martignat L., El Mansour A., Audrain M., Julien J.F., Charbonnel B., Saï P. 1995. Pancreatic expression of antigens for islet cell antibodies in non-obese diabetic mice. J. Autoimmunity 8: 465-482
25. 25. Harada M., Makino S. 1984. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 27: 604-609
26. 26. Yasunami R., Bach J.F. 1988. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur. J. Immunol. 18: 481-485
27. 27. Chicheportiche D., Darquy S., Lepeintre J., Capron F., Halban P.A., Reach G. 1990. High-performance liquid chromatography analysis of circulating insulins distinguishes between endogenous insulin production (a potential pitfall with streptozotocin diabetic rats) and islet xenograft function. Diabetologia 33: 457-461
28. 28. Saï P., Senecat O., Martignat L., Gouin E. 1994. Enhancement of diabetes in NOD mice by neonatal injections of Cyclosporin A. Clin. Exp. Immunol. 97: 138-143
29. 29. Roques M., Damgé C., Michel C., Staedel C., Crémel G., Hubert P. 1992. Encapsulation of insulin for oral administration preserves interaction of the hormone with its receptor in vitro. Diabetes 41: 451-456
30. 30. Damgé C., Michel C., Aprahamian M., Couvreur P., Devissaguet J.P. 1990. Nanocapsules as carriers for oral peptide delivery. J. Controlled Release 13: 233-239
31. 31. Michel C., Aprahamian M., Defontaine L., Couvreur P., Damgé C. 1991. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J. Pharm. Pharmacol. 43: 1-5
32. 32. Genovese S., Bonifacio E., Dean B.M., McNally J., Bosi E., Bottazzo G.F. 1992. Distinct cytoplasmic islet cell antibodies with different risk of Type I (insulin dependent) diabetes mellitus. Diabetologia 35: 385-388
33. 33. Gianani R., Pugliese A., Bonner-Weir S. 1992. Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with Type I diabetes. Diabetes 41: 347-353
34. 34. Velloso L.A., Kämpe O. Eizirik D.L., Hallberg A., Anderson A., Karlsson F.A. 1993. Human autoantibodies react with glutamic acid decarboxylase antigens in human and in rat but not in mouse islets. Diabetologia 36: 39-46
35. 35. Nayac R.C., Omar M.A.K., Rabizadeh A., Srikanta S., Eisenbarth G.S. 1985. 'Cytoplasmic' islet cell antibodies: evidence that the target antigen is a sialoglycoconjugate. Diabetes 34: 617-619
36. 36. Atkinson M.A., Kaufman D.L., Newman D., Tobin A.J., Maclaren N.K. 1993. Islet cell cytoplasmic antibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J. Clin. Invest. 91: 350-356
37. 37. Baekkeskov S., Aanstoot H.K., Christgau S., Reetz A., Solimena M., Cascalho M., Folli F., Richter-Olesen H., De Camilli P. 1990. Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347: 151-156
38. 38. Kim J., Richter W., Aanstoot H.J., Shi Y., Fu Q., Rajotte R., Warnock G., Baekkeskov S. 1993. Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets. Diabetes 42: 1799-1808
39. 39. Marshall M.O., Hoyer P.E., Petersen J.S., Hejnaes K.R., Genovese S., Dyrberg T., Bottazzo G.E 1994. Contribution of glutamate decarboxylase antibodies to the reactivity of islet cell cytoplasmic antibodies. J. Autoimmunity 7: 497-508
40. 40. Miller J.F.A.P., Morahan G. 1992. Peripheral T cell tolerance. Ann. Rev. Immunol. 10: 51-70
41. 41. Serreze D.V., Leiter E.H., Kuff E.L., Jardieu P., Ishizaka K. 1988. Molecular mimicry between insulin and retroviral antigen p73: development of cross-reactive autoantibodies in sera of NOD and C57BL/KsJ db/db mice. Diabetes 37: 351-358
42. 42. Ziegler A.G., Vardi P., Ricker A.T., Hattori M., Soeldner J.S., Eisenbarth G.S. 1989. Radioassay determination of insulin autoantibodies in NOD mice: correlation with increased risk of progression to overt diabetes. Diabetes 38: 358-363
43. 43. Zhang Z.J., Davidson L., Eisenbarth G., Weiner H.L. 1991. Suppression of diabetes in non obese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA 88: 10252-10256
44. 44. Saï P., Rivereau A.S. 1996. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments: comparative efficiency of human insulin and two bacterial antigens, lipopolysaccharide from Escherichia coll and glycoprotein extract from Klebsiella pneumoniae. Diabete. Metab. 22: 341-348
45. 45. Bowman M.A., Campbell L., Darrow B.L., Ellis T.M., Suresh A., Atkinson M.A. 1996. Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 45: 205-208
46. 46. Chaillous L., Darquy S., Maugendre S., Rivereau A.S., Reach G., Saï P. 1996. Xenografts of porcine islets immunoprotected in hollow fibres reduce the incidence of diabetes in NOD mice. Diabetologia 39: 523-529